In the run-up to the annual congress of EULAR, the most important conference in rheumatology, Janssen has announced a major research and commercialization deal with Monash University.
The collaboration between Janssen, the biotech arm of the Johnson & Johnson (NYSE: JNJ), and one of Australia’s leading academic centers is aimed at developing novel rheumatoid arthritis treatments.
Sales of the company’s blockbuster immunology drug Remicade (infliximab) have come under pressure lately, as a growing number of biosimilar therapies gain regulatory approval around the world.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze